Novartis anketi, sedef hastalarının tedavilerinde derinin temizlenmesinden fazlasını beklediğini gösteriyor
References
1. Feldman S, et al. Exploring Patient Preferences for the Treatment of Moderate to Severe Psoriasis: a Discrete Choice Experiment Study in the US, Abstract presented at EADV, 20182. Niedhardt K. Patient-Relevant Endpoints In Psoriasis – A Literature Review Of Patient Preference Studies. Value Health. 2016;19(7):a5713. Kauf T L , et al. Psoriasis patients’ willingness to accept side-effect risks for improved treatment efficacy. Journal of Dermatological Treatment. 2015;26(6):507-5134. Feldman S, et al. Journal of Health Economics and Outcomes Research. 2016;4(2):141-155. Gonzalez J M, et al. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the UK: results from a discrete-choice experiment. British Journal of Dermatology. 2017;176(3) 777-7856. Mease P J, et al. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014;74:423-41.7. International Federation of Psoriasis Associations (IFPA) World Psoriasis Day website. "About Psoriasis." Available at: http://www.worldpsoriasisday.com/web/page.aspx?refid=114. Last accessed January 2018.8. Baran R. The burden of nail psoriasis: an introduction. Dermatol. 2010:221 Suppl 1:1-5.9. Kumar B, et al. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Dermatol Venereol. 2002;82:192-5.10. Zampieron A, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015 Jun;150(3):309-1611. Menter, et al. Journal of the American Academy of Dermatology. 2008; 58(5):826-5012. Chung J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623-32.
- Yeni sonuçlanan hasta anketi, derinin temizlenmesi hastaların için en önemli unsur olmakla birlikte, hastaların tedaviden kanıtlanmış uzun dönemde etkililik ve güvenlilik verisi ile enjeksiyon yeri reaksiyonu olmaması gibi başka yararlar da beklediğini doğrulamaktadır.1
- İlave olarak, hastalar tarafından etkililiğin, sedef hastalığının çoklu belirtilerinin tedavi edilmesinde de önem taşıdığı belirtilmektedir.1
- Doz başına enjeksiyon sayısı ve enjeksiyon sıklığı, hastalar tarafından en az önem verilen faktörlerdir.1
1. Feldman S, et al. Exploring Patient Preferences for the Treatment of Moderate to Severe Psoriasis: a Discrete Choice Experiment Study in the US, Abstract presented at EADV, 20182. Niedhardt K. Patient-Relevant Endpoints In Psoriasis – A Literature Review Of Patient Preference Studies. Value Health. 2016;19(7):a5713. Kauf T L , et al. Psoriasis patients’ willingness to accept side-effect risks for improved treatment efficacy. Journal of Dermatological Treatment. 2015;26(6):507-5134. Feldman S, et al. Journal of Health Economics and Outcomes Research. 2016;4(2):141-155. Gonzalez J M, et al. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the UK: results from a discrete-choice experiment. British Journal of Dermatology. 2017;176(3) 777-7856. Mease P J, et al. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014;74:423-41.7. International Federation of Psoriasis Associations (IFPA) World Psoriasis Day website. "About Psoriasis." Available at: http://www.worldpsoriasisday.com/web/page.aspx?refid=114. Last accessed January 2018.8. Baran R. The burden of nail psoriasis: an introduction. Dermatol. 2010:221 Suppl 1:1-5.9. Kumar B, et al. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Dermatol Venereol. 2002;82:192-5.10. Zampieron A, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015 Jun;150(3):309-1611. Menter, et al. Journal of the American Academy of Dermatology. 2008; 58(5):826-5012. Chung J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623-32.
sedef hastası arkadaşlar....... 'www.sedefiyendim.com'